Abstract
Role of EGF inhibitors in the treatment of recurrent or metastatic squamous cell head and neck cancer Jochen H LorchDana Farber Cancer institute, Boston, MA, USAAbstract: Squamous cell cancer of the head and neck (SCCHN) is a major contributor to morbidity and mortality worldwide. In recent years, inhibition of the epidermal growth factor receptor has become an established treatment strategy in SCCHN both in the up-front treatment and in the recurrent and metastatic setting. This review summarizes the most important developments of the recent past and provides an overview of newer developments. Keywords: squamous cell cancer, head, neck, epidermal growth factor receptor
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
